Argenica Therapeutics Ltd
ASX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sirona Biochem Corp
XBER:ZSB
|
CA |
|
Zelluna ASA
OSE:ZLNA
|
NO |
|
C
|
Carasso Real Estate Ltd
TASE:CRSR
|
IL |
|
I
|
Immsi SpA
SWB:IMY
|
IT |
Argenica Therapeutics Ltd
Research & Development
Argenica Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Research & Development
-AU$8.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$36.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Research & Development?
Research & Development
-8.1m
AUD
Based on the financial report for Jun 30, 2025, Argenica Therapeutics Ltd's Research & Development amounts to -8.1m AUD.
What is Argenica Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-89%
Over the last year, the Research & Development growth was -35%. The average annual Research & Development growth rates for Argenica Therapeutics Ltd have been -48% over the past three years , -89% over the past five years .
